- Home
- CGAU vs CNTA Comparison
CGAU vs CNTA Comparison
Compare CGAU & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGAU | CNTA |
|---|---|---|
| Founded | 2002 | 2020 |
| Country | Canada | United Kingdom |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.5B |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CGAU | CNTA |
|---|---|---|
| Price | $17.64 | $26.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $16.00 | ★ $40.89 |
| AVG Volume (30 Days) | ★ 1.4M | 1.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.09% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.72 | N/A |
| Revenue Next Year | $13.78 | N/A |
| P/E Ratio | $11.74 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.41 | $9.60 |
| 52 Week High | $21.17 | $30.58 |
Technical Indicators
Market Signals| Indicator | CGAU | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 42.99 | 53.03 |
| Support Level | $17.51 | $21.93 |
| Resistance Level | $20.49 | $27.56 |
| Average True Range (ATR) | 0.94 | 1.22 |
| MACD | -0.28 | 0.04 |
| Stochastic Oscillator | 0.98 | 36.10 |
Price Performance
Historical ComparisonAbout CGAU Centerra Gold Inc.
Centerra Gold Inc is principally focused on operating, developing, exploring and acquiring gold and copper properties in North America, Turkey, and other markets world-wide. The company reportable operating segments are Oksut; Mount Milligan; and Molybdenum. It derives maximum revenue from Mount Milligan segment. Geographically, it operates in Turkey, United States, and Canada.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.